Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early-stage returns?

Bruce L Booth1

  • 1Atlas Venture, 890 Winter Street, Suite 320, Waltham, Massachusetts 02451, USA. bbooth@atlasventure.com

Nature Biotechnology
|November 10, 2006
PubMed
Summary
This summary is machine-generated.

Early-stage life science ventures offer compelling investment opportunities. A maturing biotechnology ecosystem supports these innovative, high-growth potential companies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

This time may be different.

Nature biotechnology·2016
Same author

In defense of life sciences venture investing.

Nature biotechnology·2011
Same author

Beyond the biotech IPO: a brave new world.

Nature biotechnology·2009
Same author

When less is more.

Nature biotechnology·2007
Same author

CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef.

Journal of immunology (Baltimore, Md. : 1950)·2005
Same author

Valuation with cash multiples.

Nature reviews. Drug discovery·2005
Same journal

Author Correction: Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates.

Nature biotechnology·2026
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
See all related articles

Area of Science:

  • Biotechnology
  • Investment Science
  • Venture Capital

Background:

  • The biotechnology sector is rapidly evolving, creating a complex investment landscape.
  • Traditional investment strategies may overlook the potential of early-stage life science companies.
  • A maturing biotech business ecosystem presents unique opportunities and challenges.

Purpose of the Study:

  • To challenge conventional investment thinking regarding early-stage life science ventures.
  • To highlight the compelling reasons for investor consideration of these companies.
  • To analyze the impact of a maturing biotechnology ecosystem on investment strategies.

Main Methods:

  • Qualitative analysis of market trends.
  • Review of venture capital investment patterns in biotechnology.

Related Experiment Videos

  • Case study analysis of successful early-stage life science ventures.

    • Main Results:

    • Early-stage life science companies demonstrate significant growth potential.
    • The expanding biotech ecosystem provides a supportive environment for innovation.
    • Investor confidence in early-stage ventures is increasing.

    Conclusions:

    • Investors should re-evaluate conventional wisdom and consider early-stage life science investments.
    • The current biotech ecosystem favors the growth and success of new ventures.
    • Strategic investment in early-stage life science is crucial for future innovation and returns.